Showing 4391-4400 of 8553 results for "".
- Breaking Business News: Cynosure to Acquire MyEllevate Surgical Suture Systemhttps://practicaldermatology.com/news/breaking-business-news-cynosure-to-acquire-myellevate-surgical-suture-system/2460791/Cynosure is acquiring the MyEllevate Surgical Suture System, which allows practitioners to place a suture support system without incisions. MyEllevate, performed with the ICLED light-guided suture system, is the first and only patented light-guided technology for use in soft tissue
- FDA Nod for Modifications to Soliton's Resonic Devicehttps://practicaldermatology.com/news/fda-nod-for-modifications-to-solitons-tattoo-removal-device/2460790/The U.S. Food and Drug Administration granted Soliton, Inc. 510(k) for modifications to its RESONIC device. The RESONIC device utilizes the RAP technology to deliver safe and effective tattoo removal and cellulite treatment and now includes an autoloading cartridge and an
- Potential Regenerative Medicine Breakthrough: Mayo Clinic Preclinical Discovery Triggers Scar-free Wound Healinghttps://practicaldermatology.com/news/potential-regenerative-medicine-breakthrough-mayo-clinic-preclinical-discovery-triggers-scar-free-wound-healing/2460788/Difficult-to-treat, chronic wounds in preclinical models healed with normal scar-free skin after treatment with an acellular product discovered at Mayo Clinic. Derived from platelets, the purified exosomal product, known as PEP, was used to deliver healing messages into cells of p
- Pulse Biosciences Survey: Clearing Pigmented Lesions is No. 1 Priority for Manyhttps://practicaldermatology.com/news/pulse-biosciences-survey-clearing-pigmented-lesions-is-no-1-priority-for-many/2460786/A majority of patients with unwanted benign lesions are interested in a new procedure to clear these lesions, according to a new survey by Pulse Biosciences that was presented at the American Academy of Dermatology (AAD) Virtual Annual Meeting. A diverse sample of 405 aesthetic patients
- Minimizing Risks of Cosmetic Procedures in Patients with Darker Skin Typeshttps://practicaldermatology.com/news/minimizing-risks-of-cosmetic-procedures-in-patients-with-darker-skin-types/2460784/With cosmetic procedures in high demand during the pandemic, Cedars-Sinai dermatologist Jasmine Obioha, MD, has seen an unfortunate side effect: botched treatments for patients of color. When performed improperly, procedures such as chemical peels and laser hair removal can inflame and
- Cynosure Expands Its Potenza RF Microneedling System with New Fusion Tip for Enhanced Topical Penetrationhttps://practicaldermatology.com/news/cynosure-expands-its-potenza-rf-microneedling-system-with-new-fusion-tip-for-enhanced-topical-penetration/2460781/The Fusion Tip is the latest addition to Cynosure's Potenza system, its four-mode RF microneedling device, which uses ultrafine needles and RF energy to penetrate the top layer of the skin, triggering the body's natural healing process to regenerate new collagen and elastin.
- New York City's Mount Sinai Launches Melanoma and Skin Cancer Centerhttps://practicaldermatology.com/news/new-york-citys-mount-sinai-launches-melanoma-and-skin-cancer-center/2460777/Mount Sinai received a second $10 million gift from the Waldman Family to open the Kimberly and Eric J. Waldman Melanoma and Skin Cancer Center at Mount Sinai. Housed within the Kimberly and Eric J. Waldman Department of Dermatology at the May
- Data Show Amgen's Otezla Benefits Patients with Mild-to-Moderate Psoriasishttps://practicaldermatology.com/news/data-show-amgens-otezla-benefits-patients-with-mild-to-moderate-psoriasis/2460775/Amgen’s Otezla (apremilast) improved measures of disease severity in adults with mild-to-moderate plaque psoriasis regardless of their Body Surface Area (BSA) involvement, according to findings from the placebo-controlled, phase 3 ADVANCE trial, presented at the AAD VMX 2021
- Promising Phase 3 Data for Oral Deucravacitinib from Bristol Myers Squibb in Psoriasishttps://practicaldermatology.com/news/promising-phase-3-data-for-oral-deucravacitinib-from-bristol-myers-squibb-in-psoriasis/2460765/In two pivotal Phase 3 trials evaluating deucravacitinib 6mg once daily for the treatment of patients with moderate to severe plaque psoriasis, significantly more patients met both co-primary endpoints—Psoriasis Area and Severity Index (PASI) 75 response and a static Physician's Global
- Sonrei Launches Three New Mineral Gel Sunscreenshttps://practicaldermatology.com/news/sonrei-launches-three-new-mineral-gel-sunscreens/2460756/Three new sunscreens are now available from Sonrei. The sunscreen collection now includes Sonrei Clearly Zinq Tinted Mineral Gel Sunscreen SPF 45